

32

 참고 문헌

1. 대한내분비학회, 대한골대사학회, 대한골다공증학회, 대한구강악안면외과학회. 비스포스포네이트와 관련된 약골(턱뼈) 괴사. 대한내분비학회지 2009;24:227-30.
2. 한국인 영양섭취기준 2010. 한국영양학회
3. Abu EO, Bord S, Horner A, Chatterjee VK, Compston JE. The expression of thyroid hormone receptors in human bone. *Bone* 1997;21:137-42.
4. Adams JS & Hewison M: Update in Vitamin D. *J Clin Endocrinol Metab* 2010;95:471-8
5. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2016;31:16-35.
6. Albertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators: a systematic review. *Climacteric* 2005;8:214-20.
7. Albright F, Bloomberg E, Smith PH. Postmenopausal osteoporosis. *Trans Assoc Am Physicians* 1940;55:298-305.
8. Ashby J, Odum J, Foster JR. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. *Regul Toxicol Pharmacol* 1997;25:226-31.
9. Azria M, Copp DH, Zanelli JM. 25 years of salmon calcitonin: from synthesis to therapeutic use. *Calcif Tissue Int* 1995;57:405-8.
10. Barnard R, Ng KW, Martin TJ, Waters MJ. Growth hormone (GH) receptors in clonal osteoblast-like cells mediate a mitogenic response to GH. *Endocrinology* 1991;128:1459-64.
11. Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. *J Bone Miner Res* 2004;19:1270-5.
12. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hosszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. *JAMA* 2002;287:847-57.
13. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. *N Engl J Med* 2006;355:125-37.
14. Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. *J Clin Endocrinol Metab* 2019;104:1623-1630.
15. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). *J Bone Miner Res* 2012;27:243-254.
16. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). *J Bone Miner Res* 2015;30:934-944.
17. Berning B, van Kuijk JW, Bennink HJ, Kicovic PM, Fauser BC. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. *Bone* 1996;19:395-9.
18. Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D, et al. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. *Osteoporos Int* 2011; DOI: 10.1007/s00198-011-1793-9.
19. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. *Stem Cells* 2001;19:180-92.

20. Bischoff-Ferrari HA, Dawson-Hughes B, Baron JA, Burckhardt P, Li R, Spiegelman D, et al. Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials. *Am J Clin Nutr* 2007;86:1780-90.
21. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav EJ, Theiler R, Wong JB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomized control trials. *Br Med J* 2009;339:b3692.
22. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA* 2005; 295: 2257-64.
23. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC. Benefit-risk assessment of vitamin D supplementation. *Osteoporosis Int* 2010;21:1121-32.
24. Black D, Reid I, Cauley J, Boonen S, Cosman F, Leung PC, et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON Pivotal Fracture Trial (PFT). *J Bone Miner Res* 2010;25:1070.
25. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. *N Eng J Med* 2005; 353: 555-65
26. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med* 2007;356:1809-22.
27. Black DM, Greenspan SL, Ensrud KB. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. *N Eng J Med* 2003;349:1207-15
28. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. *N Engl J Med* 2010;362:1761-71.
29. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *JAMA*. 2006;296:2927-38.
30. Bolland MJ, Grey A, Avenell A. Calcium supplements with or without Vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. *BMJ* 2011;342:d2040
31. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. *J Clin Endocrinol Metab* 2008;93:2149-57.
32. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. *N Engl J Med* 2004;350:1189-99.
33. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. *J Bone Miner Res* 2010;25:937-47.
34. Bonewald LF. Osteocytes as dynamic multifunctional cells. *Ann N Y Acad Sci* 2007;1116:281-90.
35. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. *Bone* 2003;32:136-41.
36. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. *J Clin Invest* 1992;90:1622-7.
37. Brown EM. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. *Subcell Biochem* 2007;45:139-67.
38. Brown JP, Prine RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. *J Bone Miner Res* 2009;24:153-61.
39. Broyles DL, Nielsen RG, Bussett EM, Lu WD, Mizrahi IA, Nunnally PA, et al. Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. *Clin Chem* 1998;44:2139-47.
40. Bryant HU, Bales KR, Paul SM, Yang H, Cole HW, Walker-Daniels J, et al. Estrogen agonist effects of selective estrogen receptor modulators in ovariectomized rat brain. *Abstr Soc Neurosci* 1997;23:2377.
41. Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. *Endocr Pract* 2020;26(Suppl 1):1-46.
42. Canalis E, Pash J, Gabbitas B, Rydziel S, Varghese S. Growth factors regulate the synthesis of insulin-like growth factor-I in bone cell cultures. *Endocrinology* 1993;133:33-8.
43. Canalis E, Pash J, Varghese S. Skeletal growth factors. *Crit Rev Eukaryot Gene Expr* 1993;3:155-66.
44. Cano A, Chedraui P, Goulis DG, et al. Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide.

- Maturitas 2018;107:7-12.
45. Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, Bauer DC, et al. Serum 25-hydroxyvitamin D concentrations and hip fractures. *Ann Intern Med* 2008;149:242-50.
 46. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. *Breast Cancer Res Treat* 2001;65:125-34.
 47. Cauley JA, Robinsons J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative Randomized Trial. *JAMA* 2003;290:1728-38.
 48. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. *Annu Rev Immunol* 1998;16:395-419
 49. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. *Growth Factors* 2004;22:233-41.
 50. Chesnut CH 3rd, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L. Salmon calcitonin: a review of current and future therapeutic indications. *Osteoporos Int* 2008;19:479-91.
 51. Chesnut CH 3rd, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, et al. Effects of Salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: Results From the QUEST study. *J Bone Miner Res* 2005;20:1548-61.
 52. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimon A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. *Am J Med* 2000;109:267-76.
 53. Civitelli R, Napoli N, Armamento-Villareal R. Use of intravenous bisphosphonates in osteoporosis. *Curr Osteoporos Rep* 2007;5:8-13.
 54. Clement-Lacroix P, Ormandy C, Lepscheux L, Ammann P, Damotte D, Goffin V, et al. Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. *Endocrinology* 1999;140:96-105.
 55. Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, et al. Identification of androgen receptors in normal human osteoblast-like cells. *Proc Natl Acad Sci U S A* 1989;86:854-7.
 56. Cooper C, Campion G, Melton LJ, 3rd. Hip fractures in the elderly: a world-wide projection. *Osteoporos Int* 1992;2:285-9.
 57. Cosman F, Adachi CJ, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, et al. *N Engl J Med*. 2016;375:1532-43.
 58. Cosman F, Cauley JA, Eastell R, et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? *J Clin Endocrinol Metab* 2014;99:4546-54.
 59. Cosman F, Lindsay R. Selective estrogen receptor modulators: Clinical spectrum. *Endocr Rev* 1999;20:418-34.
 60. Cosman F, Nieves J, Dempster D, Lindsay R. Cyclic vs daily teriparatide therapy in previously untreated postmenopausal women and in those on prior alendronate. ASBMR 31st Annual Meeting 2009.
 61. Cosman F, Nieves J, Woelfert L. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. *J Bone Miner Res* 2001;16:925-31.
 62. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analyses of therapies for postmenopausal osteoporosis. *Endocr Rev* 2002;23:508-16.
 63. Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, et al. Ibandronate for the prevention of nonvertebral fractures: A pooled analysis of individual patient data. *Osteoporos Int* 2009;20:291-7.
 64. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. *JAMA* 2002a;288:1889-97.
 65. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effects of alendronate on risk of fracture in women with low bone density but without vertebral fractures. results from the Fracture Intervention Trial. *JAMA* 1998;280:2077-82.
 66. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, et al. Endogenous hormones and the risk of hip vertebral fractures among older women. *N Engl J Med* 1998;339:733-8.
 67. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, et al. Lasofoxifene in postmenopausal women with osteoporosis. *N Engl J Med* 2010;362:686-96.
 68. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, et al. The effects of tibolone in older postmenopausal women. *N Engl J Med* 2008; 359: 697-708.
 69. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. *Am J Med* 2002;112:281-9.
 70. Dahl SG, Allian P, Marie PJ, Mauras Y, Boivin G, Ammann P, et al. Incorporation and distribution of strontium in bone. *Bone* 2001;28:446-53.
 71. Davidson M, Moffett A, Welty F. Extraskelatal effects of lasofoxifene on postmenopausal women. *J Bone Miner Res* 2005;20:S173.
 72. Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burck-

- hardt P, Fuleihan GEH, Josse RG, Lips P, et al. Yoshimura N: IOF position statement; vitamin D recommendations for older adults. *Osteoporos Int* 2010;21:1151-4.
73. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, et al., Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. *Osteoporos Int* 2008;19:449-58.
74. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. *N Engl J Med* 1997;337:1641-7.
75. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. *J Clin Endocrinol Metab* 2002;87:3609-17.
76. Delmas PD, Davis SR, Hensen J, Adami S, van Os S, Mijland EA. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. *Osteoporos Int* 2008;19:1153-60.
77. Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. *Bone* 2008;42:36-42.
78. Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. *J Clin Densitom* 2008; 11: 325-38.
79. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. *Nat Med* 2007;13:156-63.
80. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, et al. Increased bone formation in osteocalcin-deficient mice. *Nature* 1996;382:448-52.
81. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. *Osf2/Cbfa1*: a transcriptional activator of osteoblast differentiation. *Cell* 1997;89:747-54.
82. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. *Calcif Tissue Int* 2003;73:423-32.
83. Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2019;104:1595-1622.
84. Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. *Proc Nutr Soc* 2008;67:157-62.
85. Eekman DA, Vis M, Bultink IE, Derikx HJ, Dijkmans BA, Lems WF, et al. Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates. *BMC Musculoskelet Disord* 2009;10:86.
86. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. *J Rheumatol*. 2008;35:488-97.
87. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. *Science* 1988;241:84-6.
88. Eriksen EF, Mosekilde L, Melsen F. Effect of sodium fluoride, calcium, phosphate and vitamin D2 on trabecular bone balance and remodeling in osteoporotics. *Bone* 1985;6:381-9.
89. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. *JAMA* 1999;282:637-45.
90. Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: A randomized clinical trial. *Obstet Gynecol* 2004;104:443-51.
91. Ettinger B. Tibolone for prevention and treatment of postmenopausal osteoporosis. *Maturitas* 2007;57:35-8
92. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. *Blood* 2009;114:371-9.
93. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized double-blind, placebo-controlled, dose-finding studies. *J Clin Endocrinol Metab* 2001;86:4717-26.
94. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. *J Clin Invest* 1979;64(3): 729-36.
95. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. *Mol Diagn Ther* 2008;12:157-70.
96. Gennari C, Chierichetti SM, Piolini M, Vibelli C, Agnusdei D, Civitelli R, et al. *Curr Ther Res* 1985;38:298-308.
97. Giguere V, Tremblay A, Tremblay GB. Estrogen receptor B:

- Reevaluation of estrogen and anti-estrogen signaling. *Steroids* 1998;63:335-39.
98. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. *Biochim Biophys Acta* 2003;1653:1-24.
99. Globus RK, Plouet J, Gospodarowicz D. Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix. *Endocrinology* 1989;124:1539-47.
100. Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J. Rapid and robust reponse of biochemical markers of bone formation to teriparatide therapy. *Bone* 2009;45:1053-8.
101. Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, et al. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. *J Clin Invest* 2000;106:309-18.
102. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. *Ann Intern Med* 2007;146:326-39.
103. Haguenuer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. *Osteoporos Int* 2000;11:727-38.
104. Hanley DA, Granney A, Jones G, Whiting SJ, Seslie WD, Cole DE, et al. Vitamin D in adult health and disease: a review and guideline statement from osteoporosis Canada. *CAMJ* 2010;182:E610-8.
105. Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD, et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multipleascending-dose phase I trial. *J Bone Miner Res* 2010;25:463-71.
106. Harper K, Frege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? *J Bone Miner Res* 2007;22:334.
107. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. *Curr Med Opin* 2008;24:237-245.
108. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. *JAMA* 1999;282:1344-52.
109. Harvey NC, D'Angelo S, Paccou J, et al. Calcium and Vitamin D Supplementation Are Not Associated With Risk of Incident Ischemic Cardiac Events or Death: Findings From the UK Biobank Cohort. *J Bone Miner Res* 2018;33:803-11.
110. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. *J Bone Miner Res* 2009;24:425-36.
111. Heino TJ, Hentunen TA, Vaananen HK. Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-beta: enhancement by estrogen. *J Cell Biochem* 2002;85:185-97.
112. Hodsmann AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, et al. Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. *J Clin Endocrinol Metab* 2003;88:5212-20.
113. Hodsmann AB, Papaioannou A, Cranney A. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. *CMAJ* 2006;175:48.
114. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. *J Bone Miner Res* 2000;15:2-12.
115. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. *JAMA* 2004;292:490-5.
116. Hofstetter W, Wetterwald A, Cecchini MC, Felix R, Fleisch H, Mueller C. Detection of transcripts for the receptor for macrophage colony-stimulating factor, c-fms, in murine osteoclasts. *Proc Natl Acad Sci U S A* 1992;89:9637-41.
117. Hou P, Sato T, Hofstetter W, Foged NT. Identification and characterization of the insulin-like growth factor I receptor in mature rabbit osteoclasts. *J Bone Miner Res* 1997;12:534-40.
118. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. *Proc Natl Acad Sci U S A* 1999;96:3540-5.
119. Jilka RL. Molecular and cellular mechanism of the anabolic effect of intermittent PTH. *Bone* 2007;40:1434-46.
120. Johnson ML, Kamel MA. The Wnt signaling pathway and bone metabolism. *Curr Opin Rheumatol* 2007;19:376-82.
121. Kamioka H, Honjo T, Takano-Yamamoto T. A three-dimensional distribution of osteocyte processes revealed by the

- combination of confocal laser scanning microscopy and differential interference contrast microscopy. *Bone* 2001;28:145-9.
122. Kanis JA, Johnell O, Black DM, Downs RW Jr, Sarkar S, Fuerst T, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. *Bone* 2003;33:293-300.
123. Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Genari C, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. *BMJ* 1992;305:1124-8.
124. Karsdal MA, Henriksen K, Arnold M, Christiansen C. Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. *BioDrugs* 2008;22:137-44.
125. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. *J Bone Miner Res* 2007;22:149-57.
126. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res* 2015;30:3-23.
127. Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. *Endocrinology* 2008;149:6084-91.
128. Khosta S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: Reports of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2007;22:1479-91.
129. Kindmark A, Torma H, Johansson A, Ljunghall S, Melhus H. Reverse transcription-polymerase chain reaction assay demonstrates that the 9-cis retinoic acid receptor alpha is expressed in human osteoblasts. *Biochem Biophys Res Commun* 1993;192:1367-72.
130. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. *Steroid Biochem Mol Biol* 2001;76:231-8.
131. Kloosterboer HJ, Ederveen AGH. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (progestogen) treatments. *J Steroid Biochem Mol Biol* 2003;83:157-65.
132. Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. *Reprod Sci* 2008;15:984-92.
133. Kousteni S, Bilezikian JP. The cell biology of parathyroid hormone in osteoblast. *Curr Osteoporos Rep* 2008;6:72-6.
134. Krieg MA, Barkmann R, Gonnelli S, Stewart A, Bauer DC, Del Rio Barquero L, et al. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. *J Clin Densitom* 2008;11:163-87.
135. Krohn K, Schwartz EN, Chung YS, et al. X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position. *J Clin Densitom* 2019;22:501-5.
136. Langdahl B, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh N, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomized, open-label, phase 3 trial. *Lancet*. 2017;390:1585-94.
137. Lanyon LE. Osteocytes, strain detection, bone modeling and remodeling. *Calcif Tissue Int* 1993;53 Suppl 1:S102-6.
138. Lazovic G, Radivojevic U, Milosevic V, Lazovic A, Jeremic K, Glisic A. Tibolone and osteoporosis. *Arch Gynecol Obstet* 2007;276:577-81.
139. LeBoff MS, Chou SH, Murata EM, et al. Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and Omega-3 Trial (VITAL). *J Bone Miner Res* 2020;35:883-893.
140. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. *Endocrinology* 2002;143:2376-84.
141. Levy JR, Murray E, Manolagas S, Olefsky JM. Demonstration of insulin receptors and modulation of alkaline phosphatase activity by insulin in rat osteoblastic cells. *Endocrinology* 1986;119:1786-92.
142. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, et al. Two-year treatment with denosumab (MG 162) in a randomized phase 2 study of postmenopausal women with low BMD. *J Bone Miner Res* 2007;22:1832-41.
143. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. *J Bone Miner Res* 2009;24:578-88.
144. Lindsay R and Hart A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. *Br J Med* 1980;280:1207-9.
145. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogen with and with-

- out medroxyprogesterone acetate on bone in early postmenopausal women. *JAMA* 2002;287:2668-76.
146. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. *Oncologist* 2004;9:571-91.
147. Lyles KW, Collier AC, Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. *N Engl J Med* 2007;357:1799-809.
148. Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatisides, Tsekoura M. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: A double-blind placebo-controlled clinical study. *Calcif Tissue Int* 1991;49:369-72.
149. MacNeil JA, Boyd SK. Improved reproducibility of high-resolution peripheral quantitative computed tomography for measurement of bone quality. *Med Eng Phys* 2008;30:792-9.
150. Marie PJ, Amman P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. *Calcif Tissue Int* 2001;69:121-9.
151. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 1996;312:1254-9.
152. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evisenta: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. *J Natl Cancer Inst* 2004;96:1751-61.
153. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S, et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. *J Cell Biol* 2000;151:311-20.
154. McClung M, Siris E, Cummings S. Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers in postmenopausal women with low or normal BMD. *J Bone Miner Res* 2005;20:S97.
155. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. *N Engl J Med* 2001;334:333.
156. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. *Am J Med* 2013;126:13-20.
157. McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. *Menopause* 2006;13:377-86.
158. McClung MR. Bisphosphonates. *Endocrinol Metab Clin N Am* 2003; 32: 253-71.
159. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. *J Clin Invest* 2000;105:433-40.
160. Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. *Calcif Tissue Int* 2004;75:462-8.
161. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis. *N Engl J Med* 2004;350:459-68.
162. Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. *J Bone Miner Res* 2008;23:525-35.
163. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, PD Miller, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-Year results from the MOBILE study. *J Bone Miner Res*. 2005;20:1315-22.
164. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. *J Bone Miner Res* 2005;20:2105-15.
165. Miller PD. Management of osteoporosis. *Dis Mon* 1999;45:21-54.
166. Miller PD. Safety of parathyroid hormone for treatment of osteoporosis. *Curr Osteoporosis Rep* 2008;6:12-6.
167. Mizuno Y, Hosoi T, Inoue S, Ikegami A, Kaneki M, Akedo Y, et al. Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells. *Calcif Tissue Int* 1994;54:325-6.
168. Moonga BS, Adebajo OA, Wang HJ, Li S, Wu XB, Troen B, et al. Differential effects of interleukin-6 receptor activation on intracellular signaling and bone resorption by isolated rat osteoclasts. *J Endocrinol* 2002;173:395-405.
169. Mosca L, Grady D, Barrett-Connor E, Collins P, Wenger N, Abramson BL, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. *Stroke* 2009;40:147-55.
170. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 2001;344:1434-41.

171. Neuprez A, Reginster JY. Bone-forming agents in the management of osteoporosis. *Best Pract Res Clin End Met* 2008;22:869-83.
172. NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy. Osteoporosis prevention, diagnosis, and therapy. *JAMA* 2001;285:785-95.
173. Nordin BE. The effect of calcium supplementation on bone loss in 32 controlled trials in postmenopausal women. *Osteoporos Int* 2009;20:2135-43.
174. North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. *Menopause* 2021;28:973-97.
175. Notelovitz M. Androgen effects on bone & muscle. *Fertil Steril* 2002;77:34-41.
176. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. *J Bone Miner Res* 2010;25:948-59.
177. Overgaard K, Hansen MA, Nielson VA, Riis BJ, Christiansen C. Discontinuous calcitonin treatment of established osteoporosis-effects of withdrawal of treatment. *Am J Med* 1990;89:1-6.
178. Pacifici R. T cells and post menopausal osteoporosis in murine models. *Arthritis Res Ther* 2007;9:102.
179. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. *J Bone Miner Res* 2011;26:19-26.
180. Peterson CM. Estrogen and progesterone receptors: An overview for the year 2000. *J Soc Gynecol Investig* 2000;7:S3-7.
181. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultra low-dose micronized 17 β -estradiol and bone density and bone metabolism in older women: a randomized controlled trial. *JAMA* 2003;290:1042-8.
182. Qaseem A, Forciea MA, McLean RM, et al. Clinical Guidelines Committee of the American College of Physicians. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. *Ann Intern Med* 2017;166:818-39.
183. Recker RR, Marin F, Ish-Shalom S, Moricke R, Hawkins F, Kapetanios G. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. *J Bone Miner Res*. 2009;24:1354-7
184. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brani ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. *Osteoporos Int* 2000;11:83-91.
185. Reginster JY, McClung MR, Cox D. The effects of arzoxifene on fracture incidence in postmenopausal women with osteoporosis or with low bone mass [abstract OC 30]. *Osteoporos Int* 2010;21:S23.
186. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. *J Clin Endocrinol Metab* 2005;90:2816-22.
187. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. *N Engl J Med* 2002;346:653-61
188. Rhee Y, Won YY, Baek MH, Lim SK. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rates. *J Bone Miner Res* 2004;19:931-7.
189. Rico H, Hernandez ER, Revilla M, Gomez-Castresana F. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. *Bone Miner* 1992;16:131-8.
190. Riggs BL, Wahner HW, Seeman E, Offord KP, Dunn WL, Mazess RB, et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. *J Clin Invest* 1982;70:716-23.
191. Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. *J Bone Miner Res* 2001;16:1871-78.
192. Rizzoli R, Burlet N, Cahall D, Delmas PD, Erikson EF, Felsenberg D. Osteoporosis. *Bone* 2008;42:841-7.
193. Rizzoli R, Poser J, B'urburg U. Nuclear thyroid hormone receptors in cultured bone cells. *Metabolism* 1986;35:71-4.
194. Robbie-Ryan M, Pacifici R, Weitzmann MN. IL-7 drives T cell mediated bone loss following ovariectomy. *Ann N Y Acad Sci* 2006;1068:348-51.
195. Roe EB, Sanchez SD, Cann CE, del Puerto GA, Pierini E, Arnaud CD. PTH-induced increases in bone density are preserved with estrogen: results from a follow-up year in postmenopausal osteoporosis. *J Bone Miner Res* 2000;15:193.

196. Ross CA, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab* 2011;96:53-8.
197. Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? *Osteoporos Int* 2020;31:2271-86.
198. Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. *Clin Geriatr Med* 2003;19:415-32.
199. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. *J Oral Maxillofac Surg* 2014;72:1938-56.
200. Rydziel S, Shaikh S, Canalis E. Platelet-derived growth factor-AA and -BB (PDGF-AA and -BB) enhance the synthesis of PDGF-AA in bone cell cultures. *Endocrinology* 1994;134:2541-6.
201. Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. *Climacteric* 2002;5:390-8.
202. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. *N Engl J Med* 2017;11:1-11.
203. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. *N Engl J Med* 2007;357:2028-39.
204. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, et al. Annual high-dose vitamin D and falls and fractures in older women. *JAMA* 2010;303:1815-22.
205. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: An Endocrine Society Scientific Statement. *J Clin Endocrinol Metab* 2010;95:s1-s66.
206. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. *J Bone Miner Res* 2002;17:1-10.
207. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. *Bone* 2004;34:195-202.
208. Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. *J Bone Miner Res* 2010;25:976-82.
209. Seeman E, Devoqlaer JP, Lorence R, Spector T, Brixen K, Balogh A, et al. Strontium Ranelate Reduces the Risk of Vertebral Fractures in Patients With Osteopenia. *J Bone Miner Res* 2008;23:433-8.
210. Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, et al. Strontium Ranelate Reduces the Risk of Vertebral and Nonvertebral Fractures in Women Eighty Years of Age and Older. *J Bone Miner Res* 2006;21:1113-20.
211. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2014;29:1-23.
212. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2010;25:2267-94.
213. Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, et al. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. *Endocr rev* 2002;23:552-9.
214. Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, et al. WITHDRAWN: Calcium supplementation on bone loss in postmenopausal women. *Cochrane Database Syst Rev* 2007;18:CD004526.
215. Shilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft 2011;364:1728-37.
216. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. *J Clin Endocrinol Metab* 2020;105:587-94.
217. Shughrue PJ, Lane MV, Merchenthaler I. Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: An in situ hybridization study. *Endocrinology* 1997;138:5476-84.
218. Silver J, Bushinsky D. *Curr Opin Nephrol Hypertens* 2004;13:471-6.
219. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. *AM J Med* 2009;122:S33-S45.
220. Silverman SL, Maricic M. Recent developments in bisphosphonate therapy. *Semin Arthritis Rheum* 2007;37:1-12.
221. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal

- women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. *J Bone Miner Res* 2008;23:1923-34.
222. Simon LS. Osteoporosis *Rheum Dis Clin N Am* 2007;33:149-76.
223. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, L'U Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 1997;89:309-19.
224. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, et al. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. *J Clin Invest* 2004;113:379-89.
225. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. *Arch Intern Med* 2004;164:1108-12.
226. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. *J Bone Miner Res* 2005;20:1514-24.
227. Sogaard CH, Mosekilde L, Richards A, Mosekilde L. Marked decrease in trabecular bone quality after five years of sodium fluoride therapy - assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients. *Bone* 1994;15:393-9.
228. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. *Cell* 1991;64:693-702.
229. Srivastava AK, Libanati C, Hohmann O, Kriegman A, Baylink DJ. Acute effects of calcitonin nasal spray on serum C-terminal peptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover. *Calcif Tissue Int* 2004;75:477-81.
230. Steddon SJ, Cunningham J. Calcimimetics and calcilytics: fooling the calcium receptor. *Lancet* 2005;365:2237-9.
231. Steven R, Cummings, Javier San Martin, Michael R, McClung, Ethel S, Siris, Richard Eastell, Ian R, Reid, et al. Denosumab for prevention of fractures in postmenopausal women with Osteoporosis. *N Engl J Med* 2009;361:756-65.
232. Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. *Clin Pharmacol Ther* 2009;86:175-82.
233. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. *Endocr Rev* 1999;20:345-57.
234. Swarthout JT, D Alonzo RC, Selvamurugan N, Partridge NC. Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. *Gene* 2002;282:1-17.
235. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fracture and bone loss in people aged 50 years and older's meta-analysis. *Lancet* 2007;370:657-66.
236. Teitelbaum SL. Bone resorption by osteoclasts. *Science* 2000;289:1504-8.
237. Teti A, Rizzoli R, Zamboni Zallone A. Parathyroid hormone binding to cultured avian osteoclasts. *Biochem Biophys Res Commun* 1991;174:1217-22.
238. The writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *JAMA* 1996;276:1389-96.
239. Thi'baud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. *Osteoporos Int* 1994;4:76-83.
240. Thomas DM, Udagawa N, Hards DK, Quinn JM, Moseley JM, Findlay DM, et al. Insulin receptor expression in primary and cultured osteoclast-like cells. *Bone* 1998;23:181-6.
241. Torgeson DJ, Bell-Syer SEL. Hormone replacement therapy and prevention of vertebral fracture: a meta-analysis of randomized trials. *BMC Musculoskelet Disord* 2001;2:7.
242. Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone therapy is associated with significant vertebral bone loss in postmenopausal women. *Osteoporos Int* 2001;12:385-90.
243. Trevisani VFM, Riera R, Imato AM, Saconato H, Atallah AN. Teriparatide in postmenopausal women with osteoporosis: systematic review *Sao Paulo Med J* 2008;126:279-84.
244. Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. *J Cell Sci* 2000;113:377-81.
245. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. *Toxicol Pathol* 2002;30:312-21.
246. Vestergaard P, Jorgensen NR, Schwarz P, Mosekilde L. Effects of treatment with fluoride on bone mineral density and fracture risk--a meta-analysis. *Osteoporos Int* 2008;19:257-68.

247. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA* 2006;295:2727-41.
248. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. *JAMA* 1998;279:1445-51.
249. Warensjo E, Byberg L, Melhus H, Gedeberg R, Mallmin H, Wolk A, et al. Dietary calcium intake and of fracture and osteoporosis: prospective longitudinal cohort study. *BMJ* 2011;342:1473.
250. Warshawsky H, Goltzman D, Rouleau MF, Bergeron JJ. Direct in vivo demonstration by radioautography of specific binding sites for calcitonin in skeletal and renal tissues of the rat. *J Cell Biol* 1980;85:682-94.
251. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. *J Clin Endocrinol Metab* 2010;95:1555-65.
252. Weaver CM, Alexander DD, Boushey CJ, et al. vitamin D supplementation and risk of fractures: an updated metaanalysis from the National Osteoporosis Foundation. *Osteoporos Int* 2016;27:367-76.
253. Wei LL, Leach MW, Miner RS, Demers LM. Evidence for progesterone receptors in human osteoblast-like cells. *Biochem Biophys Res Commun* 1993;195:525-32.
254. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. *Osteoporos Int* 2003;14:814-22.
255. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, et al. Meta-analysis of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. *Endocr Rev* 2002;23:529-39.
256. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev* 2008;23:CD001155
257. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. *Gene* 2004;341:19-39.
258. Whiting SJ, Calvo MS. Dietary recommendation for vitamin D: a critical need for functional end point to establish an estimated average requirement1. *J Nutr* 2005;135:304-9.
259. Whyte MP. The long and the short of bone therapy. *N Engl J Med* 2006;354:860-3.
260. Women's Health Initiative Steering Committee. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial. *JAMA* 2004;291:1701-12.
261. Xu LX, Kukita T, Nakano Y, Yu H, Hotokebuchi T, Kuratani T, et al. Osteoclasts in normal and adjuvant arthritis bone tissues express the mRNA for both type I and II interleukin-1 receptors. *Lab Invest* 1996;75:677-87.
262. Yaffe K, Krueger K, Cummings SR, Blackwell T, Henderson VW, Sarkar S, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. *Am J Psychiatry* 2005;162:683-90.
263. Yang D, Guo J, Divieti P, Bringham FR. Parathyroid hormone activates PKC-delta and regulates osteoblastic differentiation via a PLC-independent pathway. *Bone* 2006;38:485-96.
264. Yates J, Barrett-Connor E, Barlas S, Chen YT, Miller P, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. *Obstet Gynecol* 2004;103:440-8.
265. Zhang Z, Chen J, Jin D. Platelet-derived growth factor (PDGF)-BB stimulates osteoclastic bone resorption directly: the role of receptor beta. *Biochem Biophys Res Commun* 1998;251:190-4.
266. Zikan V, Stepan J. Plasma type 1 collagen cross-linked Ctelopeptide: a sensitive marker of acute effects of salmon calcitonin on bone resorption. *Clin Chim Acta* 2002;316:63-9.